Corrigendum to “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications”

Figure 4

Utilisation of insulin glargine biosimilar (100 IU/ml) as a % of total insulin glargine 100 IU/ml (DDD based) over time across Europe.